JP7265984B2 - 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 - Google Patents

抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 Download PDF

Info

Publication number
JP7265984B2
JP7265984B2 JP2019521455A JP2019521455A JP7265984B2 JP 7265984 B2 JP7265984 B2 JP 7265984B2 JP 2019521455 A JP2019521455 A JP 2019521455A JP 2019521455 A JP2019521455 A JP 2019521455A JP 7265984 B2 JP7265984 B2 JP 7265984B2
Authority
JP
Japan
Prior art keywords
antibody
rsv
antibodies
antigen
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019521455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534003A5 (cg-RX-API-DMAC7.html
JP2019534003A (ja
Inventor
ローラ エム． ウォーカー，
Original Assignee
アディマブ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アディマブ， エルエルシー filed Critical アディマブ， エルエルシー
Publication of JP2019534003A publication Critical patent/JP2019534003A/ja
Publication of JP2019534003A5 publication Critical patent/JP2019534003A5/ja
Priority to JP2022066241A priority Critical patent/JP2022087247A/ja
Application granted granted Critical
Publication of JP7265984B2 publication Critical patent/JP7265984B2/ja
Priority to JP2023146398A priority patent/JP7616813B2/ja
Priority to JP2023146397A priority patent/JP2023158193A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019521455A 2016-10-21 2017-10-20 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 Active JP7265984B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022066241A JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146398A JP7616813B2 (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146397A JP2023158193A (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411510P 2016-10-21 2016-10-21
US62/411,510 2016-10-21
PCT/US2017/057708 WO2018075954A2 (en) 2016-10-21 2017-10-20 Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022066241A Division JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Publications (3)

Publication Number Publication Date
JP2019534003A JP2019534003A (ja) 2019-11-28
JP2019534003A5 JP2019534003A5 (cg-RX-API-DMAC7.html) 2020-11-26
JP7265984B2 true JP7265984B2 (ja) 2023-04-27

Family

ID=60263072

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019521455A Active JP7265984B2 (ja) 2016-10-21 2017-10-20 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2022066241A Withdrawn JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146397A Withdrawn JP2023158193A (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146398A Active JP7616813B2 (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022066241A Withdrawn JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146397A Withdrawn JP2023158193A (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146398A Active JP7616813B2 (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Country Status (4)

Country Link
US (3) US11479600B2 (cg-RX-API-DMAC7.html)
EP (1) EP3529272A2 (cg-RX-API-DMAC7.html)
JP (4) JP7265984B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018075954A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11485775B2 (en) 2016-10-21 2022-11-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3529272A2 (en) 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3528840A1 (en) 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CN119836435A (zh) * 2022-07-27 2025-04-15 胡默波斯生物医学公司 抗rsv和mpv副粘病毒的广泛中和抗体
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
WO2024259075A1 (en) * 2023-06-14 2024-12-19 Tether Therapeutics, Inc. Polymer formulations for delivery of polynucleotides
WO2025104604A1 (en) * 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
ATE231002T1 (de) 1992-09-16 2003-02-15 Scripps Research Inst Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
NZ269735A (en) 1993-07-30 1998-01-26 Oravax Inc Monoclonal iga antibody against respiratory syncytial virus (rsv)
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2230127A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
DE60025019T2 (de) 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ES2349348T3 (es) 2000-01-27 2010-12-30 Medimmune, Llc Anticuerpos neutralizantes de rsv de ultra alta afinidad.
AU2001240020B9 (en) 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
AU2001241918A1 (en) 2000-03-02 2001-09-12 Med Immune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
ES2338098T3 (es) 2000-05-03 2010-05-04 Medimmune, Llc Terapia de combinacion de enfermedades respiratorias usando anticuerpos y agentes antiinflamatorios.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
WO2004091519A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
US20090030187A1 (en) 2005-03-14 2009-01-29 Tous Guillermo I Macromolecules comprising a thioether cross-link
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
WO2008106980A2 (en) 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009030237A2 (en) 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
CA2704134A1 (en) 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
KR100938998B1 (ko) 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체
JP5575377B2 (ja) 2008-07-18 2014-08-20 シスメックス株式会社 抗ｒｓウイルスモノクローナル抗体を用いたｒｓウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗ｒｓウイルスモノクローナル抗体
ES2701649T3 (es) 2009-01-14 2019-02-25 Ablynx Nv Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
PT2438087T (pt) 2009-06-05 2017-08-04 Ablynx Nv Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
JP6450688B2 (ja) * 2013-02-01 2019-01-09 メディミューン，エルエルシー 呼吸器合胞体ウイルスｆタンパク質エピトープ
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
MX374517B (es) 2014-01-15 2025-03-06 Medimmune Ltd Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos.
AU2015340056A1 (en) * 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
US11485775B2 (en) 2016-10-21 2022-11-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3529272A2 (en) 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3528840A1 (en) 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIRGITTE K GIERSING，VACCINE，NL，2016年04月25日，VOL:37，PAGE(S):7355 - 7362，http://dx.doi.org/10.1016/j.vaccine.2017.02.068
DAVIDE CORTI et al.，CROSS-NEUTRALIZATION OF FOUR PARAMYXOVIRUSES BY A HUMAN MONOCLONAL ANTIBODY，NATURE，2013年09月19日，VOl. 501，p. 439-443, SUPPLEMENTARY INFORMATION，http://dx.doi.org/10.1038/nature12442
JASON S MCLELLAN，NEUTRALIZING EPITOPES ON THE RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN，CURRENT OPINION IN VIROLOGY，英国，2015年04月01日，VOL:11，PAGE(S):70 - 75，http://dx.doi.org/10.1016/j.coviro.2015.03.002
Jiachen Huang et al.，Frontiers in Immunology，2019年11月，Vol. 10, Article 2778，p. 1-8
NGWUTA J O，PREFUSION F-SPECIFIC ANTIBODIES DETERMINE THE MAGNITUDE OF RSV NEUTRALIZING ACTIVITY IN HUMAN SERA，SCIENCE TRANSLATIONAL MEDICINE，米国，2015年10月14日，VOL:7, NR:309，PAGE(S):309RA162 (1 - 9)，http://dx.doi.org/10.1126/scitranslmed.aac4241
SCHUSTER J E，JOURNAL OF INFECTIOUS DISEASES，米国，2014年05月26日，VOL:211, NR:2，PAGE(S):216 - 225，http://dx.doi.org/10.1093/infdis/jiu307

Also Published As

Publication number Publication date
JP2023158193A (ja) 2023-10-26
JP2022087247A (ja) 2022-06-09
US11479600B2 (en) 2022-10-25
US20250313612A1 (en) 2025-10-09
US20190256580A1 (en) 2019-08-22
WO2018075954A3 (en) 2018-09-20
JP7616813B2 (ja) 2025-01-17
WO2018075954A2 (en) 2018-04-26
US12215141B2 (en) 2025-02-04
JP2019534003A (ja) 2019-11-28
JP2023158194A (ja) 2023-10-26
EP3529272A2 (en) 2019-08-28
US20230303668A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
JP7524155B2 (ja) 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP7644040B2 (ja) 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP7616813B2 (ja) 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
WO2019075433A1 (en) ANTIBODIES AGAINST SYNCYTIAL RESPIRATORY VIRUS AND METHODS FOR THEIR GENERATION AND USE
US20250388653A1 (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
HK40072255A (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230417

R150 Certificate of patent or registration of utility model

Ref document number: 7265984

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150